AKBA Akebia Therapeutics Inc.

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.

Guggenheim Healthcare Innovation Conference

Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.

Jefferies Global Healthcare Conference

Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.

A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at  following the conferences.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
04/11/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November...

November 4, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 51,825 shares of Akebia’s common stock on October 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exerc...

November 3, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and...

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on November 10, 2025, at 8:00 a.m. EST CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, prior to the open of financial markets. Akebia will host a conference call on Monday, November 10, 2025, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please r...

October 30, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patient...

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that after meeting with the U.S. Food and Drug Administration (FDA) it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage c...

October 28, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 20...

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2025 (ASN Kidney Week), which will take place in Houston, TX from November 5-9, 2025. ASN K...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch